Skip to main content

Table 3 Observed maximum concentration (Cmax) and concentration after 28 days (C28) following three doses of CAT-354 (PK population)

From: A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

 

CAT-354

 

1 mg/kg

5 mg/kg

10 mg/kg

Cmax (μg/mL)

   

   Dose 1

30.3 (5.2) [n = 8]

157 (34.5) [n = 8]

306 (31.4) [n = 3]

   Dose 2

35.0 (6.8) [n = 7]

161 (32.8) [n = 7]

298 (-) [n = 1]

   Dose 3

41.1 (4.8) [n = 6]

179 (25.4) [n = 7]

393 (-) [n = 1]

C28 (μg/mL)

   

   Dose 1

5.3 (1.3) [n = 8]

27.1 (4.9) [n = 7]

40.7 (-) [n = 1]

   Dose 2

7.7 (1.6) [n = 6]

36.0 (11.5) [n = 7]

59.4 (-) [n = 1]

   Dose 3

8.6 (2.0) [n = 6]

40.6 (12.3) [n = 7]

79.6 (-) [n = 1]

  1. Note: Values are arithmetic mean (SD).
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us